The Last Children of Down Syndrome
By Sarah Zhang,
The Atlantic
| 11. 18. 2020
Prenatal testing is changing who gets born and who doesn’t. This is just the beginning.
Photo by Nathan Anderson on Unsplash
Every few weeks or so, Grete Fält-Hansen gets a call from a stranger asking a question for the first time: What is it like to raise a child with Down syndrome?
Sometimes the caller is a pregnant woman, deciding whether to have an abortion. Sometimes a husband and wife are on the line, the two of them in agonizing disagreement. Once, Fält-Hansen remembers, it was a couple who had waited for their prenatal screening to come back normal before announcing the pregnancy to friends and family. “We wanted to wait,” they’d told their loved ones, “because if it had Down syndrome, we would have had an abortion.” They called Fält-Hansen after their daughter was born—with slanted eyes, a flattened nose, and, most unmistakable, the extra copy of chromosome 21 that defines Down syndrome. They were afraid their friends and family would now think they didn’t love their daughter—so heavy are the moral judgments that accompany wanting or not wanting to bring a child with a disability into the world.
All of these people get in...
see more
Related Articles
By Sarah Zhang, The Atlantic | 06.22.2022
Photo by ANIRUDH on Unsplash
In October 2019, Jordan Janz became the first person in the world to receive an experimental therapy for cystinosis, a rare genetic disease. The treatment was physically grueling. Doctors extracted blood stem cells from Janz’s...
By Ian Sample , The Guardian | 06.22.2022
More than half the UK backs the idea of rewriting the DNA of human embryos to prevent severe or life-threatening diseases, according to a survey.
Commissioned by the Progress Educational Trust (PET), a fertility and genomics charity, the Ipsos poll...
By Fiorella Valdesolo, WSJ Magazine | 06.08.2022
“Where is the we?” It’s the question that was the driving force for Vida Delrahim and Ronit Menashe when they created WeNatal, a new brand of prenatal supplements that aims to be more inclusive. In the process of trying...
By Michael Le Page, New Scientist | 06.16.2022
CRISPR gene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat...